FEATURE ARTICLES
As an icebreaker to start the panel, Teresa Minero from LifeBee asked each presenter to share their top recommendations and major issues to avoid with AI.
- November 2025 — CDMO Opportunities And Threats Report
- What 2025 FDA Warning Letters Tell Us About GMP Compliance
- Unpacking The EU's Mutual Recognition Agreements For Pharma
- It's Copy/Paste In Fleet Management Manufacturing
- The Module Type Package Wants All Your Equipment To Start Talking
- FDA Issues Final Guidance For pH Adjuster Waiver Requests For Generic Drugs
- Leveraging Historical Data to Accelerate Process Understanding
PHARMA ONLINE WHITE PAPERS
-
![getty-1311598658-data-analytics]( "Exploring The Potential Of Agentic AI")
Exploring The Potential Of Agentic AIDiscover how agentic AI is poised to transform Enterprise Asset Management in regulated industries to enhance compliance, reduce downtime, and bridge fragmented systems for resilient operations.
-
Avoiding The Pitfalls Of PQR10/9/2024
Explore the fundamentals of Product Quality Reviews (PQRs), common challenges manufacturers face, strategies for streamlining PQRs, and solutions that aim to unlock the potential of a "real-time PQR."
-
Molecular Approaches To Streamline Cell Therapy Product Analytical Testing9/26/2025
Learn how rapid molecular methods of cell therapy testing like qPCR for mycoplasma, sterility, and lentiviral quantification are key to accelerating product release and timely treatment delivery.
-
Navigating Digital Transformation For Pharmaceutical CDMOs10/31/2025
Discover how CDMOs can modernize operations, safeguard data integrity, and improve audit readiness with practical strategies for connecting systems and reducing validation burdens.
-
Guide To Pharmaceutical CAPA And Quality Management3/14/2025
CAPA management is vital for quality systems, especially in pharmaceuticals. Examine how issues are identified, corrected, and prevented to safeguard health and uphold regulatory compliance.
-
Placing Drug Strategies On A Solid Foundation For Success9/3/2025
Explore how certain drivers are impacting traditional drug development strategies and relationships with outsourced drug development and manufacturing partners.
PHARMA ONLINE APP NOTES & CASE STUDIES
- Accelerating Cold Chain Expansion: Responding To COVID-19 Challenges
- Vial Adapter Transfer Device Compatibility With Cell Therapies
- A Closer Look At Multi-Lane Checkweighing In Pharma
- Innovative ASD Technology Improves Abandoned Cancer Medication
- Determining The Power Numbers For A Single-Use Mixing System
NEWSLETTER ARCHIVE
INDUSTRY NEWS
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
![business peope negotiating-GettyImages-637902194]( "9 Drugs Granted Fast Track By FDA's Voucher Program")
9 Drugs Granted Fast Track By FDA's Voucher ProgramWith targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
![Pharmaceutical sorting machine, pills-GettyImages-1499814881]( "Leaders In The Excipient Market: Region And Type")
Leaders In The Excipient Market: Region And TypeThough North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
-
![GettyImages-2189405678-GLP-1-obesity]( "Pfizer Strengthens Obesity Foothold With Metsera Acquisition")
Pfizer Strengthens Obesity Foothold With Metsera AcquisitionAfter discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
-
![weight loss, diabetes, insulin pen-GettyImages-2196049931]( "FDA Cracks Down On GLP-1 Imports")
FDA Cracks Down On GLP-1 ImportsGLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Samsung Biologics Expands U.S. Manufacturing Capabilities With Strategic Acquisition Of Human Genome Sciences From GSK12/22/2025
This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site, a significant expansion of the company’s global footprint and its long-term commitment to the U.S. market.
-
Techceuticals Releases 2026 Schedule For In-Person Solid Dosage Manufacturing Training12/19/2025
Techceuticals has announced its 2026 training schedule for solid dosage manufacturing, featuring a full lineup of two-day, hands-on courses covering tablet making, encapsulation, granulation, film coating, and end-to-end solid dosage processes.
-
Sanofi Toronto Equipment Assets Auction Announced For January 202612/19/2025
Federal Equipment Company, a trusted global provider of surplus pharmaceutical and chemical processing equipment, announced it will conduct a two-day online auction on behalf of Sanofi featuring quality process and laboratory equipment surplus to the company’s ongoing operational needs.
-
Alnylam Announces $250M Investment To Expand U.S. Manufacturing Capacity In Massachusetts For RNAi Therapeutics12/18/2025
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry’s first fully dedicated, proprietary, siRNA enzymatic-ligation manufacturing facility. This investment is expected to meaningfully expand capacity, significantly reduce production costs, and position Alnylam to support future launches across its growing pipeline of potential new medicines.
-
Driving Pharma 4.0: Flexible & Sustainable Facilities At PHARMAP 202612/18/2025
The shift towards Pharma 4.0 is revolutionising pharmaceutical manufacturing, introducing highly advanced, digitally interconnected and automated production plants that simplify processes and transform the industry. The future of pharmaceutical facilities is going to be the central theme of discussions at PHARMAP 2026 in Amsterdam on 20-21 April.
